Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly, which makes Zepbound and Mounjaro, reports that in a phase one clinical trial, a once daily GLP-1 pill helped lower the hemoglobin A1C, a measure of blood sugar control, in people with type ...

Zoom out: The positive results sent Lilly's stock soaring 16% Thursday to $852. Bank of America's Anderson projected 2030 ...

Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or ...

In a bid to shed a few pounds and combat her type 2 diabetes diagnosis, Karen Coe from Hailsham in East Sussex, was ...

Novo Nordisk’s India launch comes amid growing demand for glucagon-like peptide-1 (GLP-1)-based therapies, and follows the recent rollout of Mounjaro by Eli Lilly, a dual GLP-1/glucose-dependent ...

Eli Lilly launches higher doses of Zepbound, lowers price of certain vials Lilly also said they have "long been concerned" about counterfeit, compounded and any unapproved tirzepatide in the ...